1-3 of 3
Jung H. Woo
Close
Sort by
Journal Articles

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Clinical Trials & Observations
Arthur E. Frankel, Jung H. Woo, Chul Ahn, Naveen Pemmaraju, Bruno C. Medeiros, Hetty E. Carraway, Olga Frankfurt, Stephen J. Forman, Xuezhong A. Yang, Marina Konopleva, Francine Garnache-Ottou, Fanny Angelot-Delettre, Christopher Brooks, Michael Szarek, Eric Rowinsky
Journal: Blood
Blood (2014) 124 (3): 385–392.
https://doi.org/10.1182/blood-2014-04-566737
Published: 2014
Journal Articles

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Arthur E. Frankel, MD, Jung H. Woo, PhD, Jeremy P. Mauldin, PhD, Hetty E. Carraway, MD, MBA, Olga Frankfurt, MD, Stephen J. Forman, MD, Sumithira Vasu, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, Francine Garanache-Ottou, Ph.D., Fanny Angelot-Delettre, PhD, Christopher Brooks, PhD, Michael Szarek, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD
Journal: Blood
Blood (2013) 122 (21): 2682.
https://doi.org/10.1182/blood.V122.21.2682.2682
Published: 2013
Journal Articles

An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas--CTCL

Arthur E. Frankel, MD, Jung H Woo, PhD, Jeremy P Mauldin, PhD, Francine M. Foss, MD, Madeleine Duvic, MD, David M Neville, Jr., MD
Journal: Blood
Blood (2013) 122 (21): 4381.
https://doi.org/10.1182/blood.V122.21.4381.4381
Published: 2013